Could a common diabetes drug curb weight gain in people with intellectual disabilities?

NCT ID NCT05744479

Recruiting now Disease control Sponsor: Centre for Addiction and Mental Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether metformin, a diabetes drug, can help adults with intellectual disabilities who have gained weight from antipsychotic medications. One hundred participants will receive either metformin or a placebo for 24 weeks, along with lifestyle advice. The goal is to see if metformin can safely reduce weight and improve health in this often-overlooked group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin
What this could lead to: If it works, this could provide a safe and accessible medication option to help manage weight gain caused by antipsychotics in people with intellectual disabilities.
What could go wrong: This is a small Phase 4 trial with only 100 participants, and metformin may not work for everyone. Side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL DISABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental disability intellectual disability Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEVELOPMENTAL DISABILITY INTELLECTUAL DISABILITY OBESITY

Contacts and locations

Locations

Centre for Addiction and Mental Health
RECRUITING

Toronto, Ontario, M6J1H3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.